In a significant milestone for U.S. healthcare policy, President Donald Trump has announced new pricing agreements with Eli Lilly and Novo Nordisk that will dramatically reduce the cost of weight-loss medications for American patients. The deals represent a major achievement in Trump’s longstanding commitment to lower prescription drug prices and expand access to essential therapies.

Under the new agreements, Eli Lilly’s Zepbound (tirzepatide) will be priced at an average of $346 per month, down from the current $1,086. Novo Nordisk’s Wegovy (semaglutide) and Ozempic (semaglutide) will be offered at $350 per month, a steep reduction from their existing $1,000–$1,350 monthly cost range. These discounted prices will be available through TrumpRx, the U.S. government’s new direct-to-consumer (DTC) platform set to launch in January 2026.

The initiative also broadens coverage under Medicare and Medicaid, with co-payments on Medicare expected to be as low as $50 per month. This expansion will significantly improve access to GLP-1 receptor agonists (GLP-1RAs), a class of drugs that has revolutionized obesity and diabetes management.

“Today marks a pivotal moment in U.S. healthcare policy and a defining milestone for Lilly, made possible through collaboration with the Trump Administration,” said David Ricks, CEO of Eli Lilly.

GlobalData Life Sciences research analyst Cyrus Fan noted that the move could reshape the obesity treatment landscape: “The inclusion of GLP-1RA drugs under Medicare coverage means millions more patients will have access to weight-loss therapies. This also paves the way for future GLP-1RA drugs approved for weight management to receive government program coverage.”

President Trump underscored the broader significance of the agreements in a statement from the White House on November 6, saying:

“Our citizens have paid massively higher prices than other nations for the same medicines, effectively subsidizing socialism abroad while facing skyrocketing costs at home. Those days are over.”

As part of the deals, both companies will receive a three-year period of tariff relief, mirroring similar agreements recently reached by Pfizer and AstraZeneca under the administration’s Most Favored Nation (MFN) pricing framework. The MFN policy aims to align U.S. drug prices with the lowest levels found in other developed countries.

In addition to injectable therapies, the agreements cover upcoming oral weight-loss drugs, including Lilly’s orforglipron and Novo’s oral Wegovy, both expected to launch at $149 per month for the lowest dose. Oral formulations are projected to accelerate market growth beyond what injectable GLP-1RAs have achieved to date.

Eli Lilly has applied for the Commissioner’s National Priority Voucher for orforglipron, part of a new FDA framework designed to fast-track approval for drugs serving key U.S. public health priorities. GlobalData projects orforglipron could reach $11 billion in annual sales by 2031, with Lilly investing heavily in new manufacturing facilities to meet anticipated demand.

Novo Nordisk acknowledged a potential “low single-digit impact” on global sales growth in 2026 due to the pricing cuts but remains confident in long-term market expansion driven by greater accessibility. Analysts at Citi added that while pricing concessions may affect margins, “increased patient volumes are likely to more than offset the reductions.”

With these landmark deals, Eli Lilly and Novo Nordisk join Pfizer and AstraZeneca in aligning with the Trump Administration’s historic drug pricing reforms — a move poised to redefine affordability, accessibility, and competition in the U.S. pharmaceutical market.